leisure time -WSS

leisure time

author：explore 2025-09-05 06:04:24 - browse：478

Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： 2 US Navy sailors arrested for allegedly spying for China

leisure time

focus

WSS

Here's how to stay safe from wildfire smoke amid reduced air quality

Microsoft strikes partnership with Duke Health to advance health AI

Belarusian journalist sentenced to 4 years in prison as crackdown continues

Who is Magistrate Judge Moxila Upadhyaya in Trump's Jan. 6 case?

Eating disorder hotline's move to chatbot carried cost for volunteers

Illumina to lay off 10% of research and development team

focus

leisure time

entertainment

Alkermes shareholders re

Who is Magistrate Judge Moxila Upadhyaya in Trump's Jan. 6 case?

Walensky prepares to leave CDC — and Congress — behind

Illumina to lay off 10% of research and development team

In age of alternative facts, a scholarly course on calling out crap

Anger, defiance, fear over Supreme Court decision to block student loan forgiveness

Wildfire smoke exposes gaps in outdoor worker protections

What Mike Pence has said that could be used in a Donald Trump trial

As demand for Covid shots wanes, Moderna seeks its next success

Attacks on the drug industry will lead to fewer breakthroughs

focus

Wildfire smoke map: Which US cities are forecast to be impacted by fires burning in Canada

'Ancient DNA,' 23andMe reveal African American ancestries

Ukrainian soldiers say they owe lives to US

GOP inquiry over gain

Lilly’s obesity pill cuts 15% of weight at highest dose in mid

ADA: All diabetes patients should be screened for liver condition

leisure time

leisure time

focus

leisure time